抗体药物偶联物（ADC）由单克隆抗体（mAb）通过化学接头与细胞毒性药物共价连接而成，是一种有前途的肿瘤免疫疗法。 ADC 还面临着许多挑战，包括不可避免的副作用、耐药性、肿瘤靶向和有效负载释放。为了解决这些问题，除了优化ADC的各个组成部分，如新的有效负载、连接位点和新的靶标，以及使用双特异性抗体来提高精度外，还应注意优化ADC的剂量。目前有7种ADC经美国食品药品监督管理局 (FDA) 批准上市用于治疗血液恶性肿瘤，还有数十种其他 ADC 正在临床试验或正在申请上市。在最近针对血液恶性肿瘤的 ADC 临床研究中，除了验证不同适应症的有效性外，研究人员还尝试将 ADC 与其他化疗药物联合使用，以期提高治疗效果。此外，双特异性抗体的出现可能会提高ADC的安全性和有效性。该综述总结了ADC在血液恶性肿瘤中的研究进展、面临的挑战以及未来提高ADC疗效的可能方向，可以提供新的见解探讨 ADC 在血液恶性肿瘤治疗中的未来探索。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Antibody-drug conjugates (ADCs), consisting of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers, are a kind of promising tumor immunotherapy. ADCs also face a number of challenges, including unavoidable adverse effects, drug resistance, tumor targeting and payload release. To address these issues, in addition to optimizing the individual components of ADCs, such as new payloads, linkage sites and new targets, and using bispecific antibodies to increase precision, attention should be paid to optimizing the dosage of ADCs.There are currently 7 ADCs approved for marketing by the Food and Drug Administration (FDA) for hematological malignancies, and dozens of other ADCs are either in clinical trials or in the process of applying for marketing. In recent clinical studies targeting ADCs in hematologic malignancies, in addition to validating effectiveness in different indications, researchers have attempted to combine ADCs with other chemotherapeutic agents in anticipation of increased therapeutic efficacy. Furthermore, the availability of bispecific antibodies may increase the safety and efficacy of ADCs.This review summarized the progress of research on ADCs in hematological malignancies, the challenges being faced, and possible future directions to improve the efficacy of ADCs, which can provide novel insight into the future exploration of ADCs in the treatment of hematological malignancies.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.